Table 1.
Proliferation, phenotype and IFN-γ response of activated CD4+ or CD8+ T cells
T cell subset and cytokines |
Prolif. X-fold |
FACS (%) | IFN-γ (%) positive among CD4+ or CD8+ cells |
||||
---|---|---|---|---|---|---|---|
CD4+ | CD8+ | no-stim | MCA205 | MCA207 | Anti-CD3 | ||
CD4+, IL-7/IL-23 | 1,123 | 97 | 0.3 | 0 | 31 | 0.8 | 91 |
CD8+, IL-7/IL-23 | 2,673 | 0.3 | 96 | 0.2 | 32 | 0.3 | 97 |
CD4+, IL-2/IL-7 | 3,447 | 99 | 0.2 | 0 | 5 | 0.1 | 70 |
CD8+, IL-2/IL-7 | 12,174 | 0.2 | 95 | 0.2 | 13 | 0.5 | 93 |
CD62Llow T cells were isolated from tumor-draining lymph nodes and CD4+ or CD8+ subsets were additionally purified and activated with anti-CD3 mAb on day 0–2 and day 23 and were maintained in IL-2 + IL-7 or in IL-7 + IL-23. The total proliferation over the 29 day culture period was calculated. The phenotype of each culture was determined by FACS staining. The IFN-γ production in response to incubation with the MCA 205 tumor used for priming of LNs or an antigenically distinct tumor MCA 207 or anti-CD3 mAb was determined.